Use of recombinant factor Vlla (NovoSeven((R))) to reduce postoperative bleeding after total hip arthroplasty in a patient with cirrhosis and thrombocytopenia.
Slappendel R, Huvers FC, Benraad B, Novakova I, van Hellemondt GG
Anesthesiology 2002;96(6):1525-1527.
Review by
The effect of recombinant factor VIIa on coagulopathic pigs with grade V liver injuries.
Schreiber MA, Holcomb JB, Hedner U, Brundage SI, Macaitis JM, Hoots K
J Trauma 2002;53(2):252-257.
Review by Aldouri M
Early use of recombinant factor VIIa improves mean arterial pressure and may potentially decrease mortality in experimental hemorrhagic shock: A pilot study.
Lynn M, Jerokhimov I, Jewelewicz D, et al.
J Trauma 2002;52(4):703-707.
Review by
Use of recombinant factor VII in hepatology.
Romero Castro R, Barroso Relinque N, Caunedo Alvarez AC, et al.
Rev Esp Enferm Dig 2001;93(10):664-668.
Review by
Recombinant activated factor VII (RFVIIa) acutely normalizes prothrombin time in patients with cirrhosis during bleeding from oesophageal varices.
This is a new open-label study, which showed efficacy of rFVIIa in normalising prothrombin time and effective control of bleeding esophageal varices in cirrhotic patients,... Read More
NATA: Network for the Advancement of Patient Blood Management, Haemostasis and Thrombosis
MISSION: Providing a multidisciplinary forum for dialogue between haematologists, transfusion medicine specialists, anaesthesiologists, intensive care and emergency physicians, surgeons, perfusionists, nurses, biomedical scientists and other healthcare professionals.
Sitemap
Contact us
- secretary@nataonline.com
-
NATA
Rue de l’Industrie 24
1040 Bruxelles - VAT: 0781668659